Stock Price & Analysis

Sell PEN stock as insider selling activity and mixed institutional sentiment indicate potential weakness.

The price prediction for PEN stock in 2025 is expected to reach $290-$300. This forecast is supported by positive analyst sentiment, with several firms raising their price targets, and favorable technical indicators such as a low RSI and bullish MACD.

The S1 support level for PEN Stock is $258.78 ,The R1 resistant level for PEN Stock is $287.54.

As of the end of day on 2025-03-17, the price of PEN Stock was $272.36.

The target price for PEN Stock according to analyst rating is 307.93, with the highest price target at 340.00 and the lowest at 260.00. Analysts have a Strong Buy rating on PEN Stock overall.

The market cap of PEN is $10.5B.

PEN appears overvalued based on its current financial metrics and market sentiment. Its price-to-earnings ratio of 66.79 and EV/EBITDA of 24.12 are significantly higher than industry averages, suggesting a premium valuation. The stock's price-to-sales ratio of 7.87 and price-to-book ratio of 7.94 further indicate elevated valuations. Analysts are mixed, with some raising price targets but others citing limited upside. The stock's technical indicators, such as its Fibonacci levels and RSI of 38.40, also suggest bearish momentum. Overall, PEN's valuation metrics and mixed sentiment point to a potentially overvalued stock.

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

The price prediction for PEN stock by 2030 is approximately $450 per share. This forecast is based on Penumbra Inc.'s strong position in the medical devices industry, consistent revenue growth, and expansion into innovative healthcare technologies.

PEN has a total of 4200 employees.